SINEMET CR 200/50 Tablets
Co-Careldopa (Levodopa, Carbidopa)
"200mg, 50mg"
Merck Sharp & Dohme B.V.
| Pack size | 100's |
|---|---|
| Dispensing mode | POM |
| Source | NETHERLANDS |
| Agent | CITY MEDICAL STORE |
| Retail Price | 291.00 AED |
Available as:
Indications
SINEMET CR 200/50 Tablets is used for:
LEVODOPA
For the treatment of idiopathic parkinson's disease (paralysis agitans), postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication, and manganese intoxication
CARBIDOPA
For treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism
For the treatment of idiopathic parkinson's disease (paralysis agitans), postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication, and manganese intoxication
CARBIDOPA
For treatment of the symptoms of idiopathic parkinson's disease (paralysis agitans), post-encephalitic parkinsonism
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Co-Careldopa (Levodopa, Carbidopa) :
Mechanism of Action
LEVODOPA
Striatal dopamine levels in symptomatic parkinson's disease are decreased by 60 to 80%, striatal dopaminergic neurotransmission may be enhanced by exogenous supplementation of dopamine through administration of dopamine's precursor, levodopa. A small percentage of each levodopa dose crosses the blood-brain barrier and is decarboxylated to dopamine. This newly formed dopamine then is available to stimulate dopaminergic receptors, thus compensating for the depleted supply of endogenous dopamine
CARBIDOPA
When mixed with levodopa, carbidopa inhibits the peripheral conversion of levodopa to dopamine and the decarboxylation of oxitriptan to serotonin by aromatic l-amino acid decarboxylase. This results in increased amount of levodopa and oxitriptan available for transport to the cns. Carbidopa also inhibits the metabolism of levodopa in the gi tract, thus, increasing the bioavailability of levodopa
Striatal dopamine levels in symptomatic parkinson's disease are decreased by 60 to 80%, striatal dopaminergic neurotransmission may be enhanced by exogenous supplementation of dopamine through administration of dopamine's precursor, levodopa. A small percentage of each levodopa dose crosses the blood-brain barrier and is decarboxylated to dopamine. This newly formed dopamine then is available to stimulate dopaminergic receptors, thus compensating for the depleted supply of endogenous dopamine
CARBIDOPA
When mixed with levodopa, carbidopa inhibits the peripheral conversion of levodopa to dopamine and the decarboxylation of oxitriptan to serotonin by aromatic l-amino acid decarboxylase. This results in increased amount of levodopa and oxitriptan available for transport to the cns. Carbidopa also inhibits the metabolism of levodopa in the gi tract, thus, increasing the bioavailability of levodopa
Note
SINEMET CR 200/50 "200mg, 50mg" Tablets manufactured by Merck Sharp & Dohme B.V.. Its generic name is Co-Careldopa (Levodopa, Carbidopa). SINEMET CR 200/50 is availble in United Arab Emirates.
Farmaco UAE drug index information on SINEMET CR 200/50 Tablets is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.